Abstract
Inflammatory bowel disease (IBD) â consisting of ulcerative colitis and Crohnâs disease â is a complex, heterogeneous, immune-mediated inflammatory condition with a multifactorial aetiopathogenesis. Despite therapeutic advances in this arena, a ceiling effect has been reached with both single-agent monoclonal antibodies and advanced small molecules. Therefore, there is a need to identify novel targets, and the development of companion biomarkers to select responders is vital. In this Perspective, we examine how advances in machine learning and tissue engineering could be used at the preclinical stage where attrition rates are high. For novel agents reaching clinical trials, we explore factors decelerating progression, particularly the decline in IBD trial recruitment, and assess how innovative approaches such as reconfiguring trial designs, harmonizing end points and incorporating digital technologies into clinical trials can address this. Harnessing opportunities at each stage of the drug development process may allow for incremental gains towards more effective therapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769â2778 (2017).
Kaplan, G. G. & Windsor, J. W. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 18, 56â66 (2021).
Alatab, S. et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990â2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 17â30 (2020).
Berre, C. L., Honap, S. & Peyrin-Biroulet, L. Ulcerative colitis. Lancet 402, 571â584 (2023).
Torres, J., Mehandru, S., Colombel, J. F. & Peyrin-Biroulet, L. Crohnâs disease. Lancet 389, 1741â1755 (2017).
Gower-Rousseau, C. et al. Validation of the inflammatory bowel disease disability index in a population-based cohort. Gut 66, 588â596 (2017).
Mulder, D. J., Noble, A. J., Justinich, C. J. & Duffin, J. M. A tale of two diseases: the history of inflammatory bowel disease. J. Crohns Colitis 8, 341â348 (2014).
Svartz, M. The treatment of 124 cases of ulcerative colitis with salazopyrine and attempts of desensibilization in cases of hypersensitiveness to sulfa. Acta Med. Scand. 131, 465â472 (1948).
Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273â286 (2019).
Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009â2018. JAMA 323, 844â853 (2020).
DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20â33 (2016).
Dowden, H. & Munro, J. Trends in clinical success rates and therapeutic focus. Nat. Rev. Drug Discov. 18, 495â496 (2019).
Sands, B. E. et al. Mongersen (GED-0301) for active Crohnâs disease: results of a phase 3 study. Am. J. Gastroenterol. 115, 738â745 (2020).
Peyrin-Biroulet, L. et al. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol. Hepatol. 7, 128â140 (2022).
Rubin, D. T. et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol. Hepatol. 7, 17â27 (2022).
Harris, M. S., Wichary, J., Zadnik, M. & Reinisch, W. Competition for clinical trials in inflammatory bowel diseases. Gastroenterology 157, 1457â1461.e2 (2019).
AbbVieâs revenue from top product Humira from 2011 to 2023. Statista https://www.statista.com/statistics/318206/revenue-of-humira/ (2024).
Projected leading 10 pharmaceutical products worldwide based on lifetime sales as of 2028. Statista https://www.statista.com/statistics/1089322/top-drugs-by-lifetime-sales-globally/ (2024).
Wingrove P. Stelara patent deal puts J&J back on path to $57âbillion 2025 revenue forecast. Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/stelara-patent-deal-puts-jj-back-path-57-bln-2025-revenue-forecast-2023-06-05/ (2023).
Uzzan, M. et al. Declining enrolment and other challenges in IBD clinical trials: causes and potential solutions. J. Crohns Colitis 17, 1066â1078 (2023).
Alsoud, D., Verstockt, B., Fiocchi, C. & Vermeire, S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol. Hepatol. 6, 589â595 (2021).
Magro, F. et al. Has the therapeutical ceiling been reached in Crohnâs disease randomized controlled trials? A systematic review and metaâanalysis. U. Eur. Gastroenterol. J. 11, 202â217 (2023).
Schett, G., McInnes, I. B. & Neurath, M. F. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N. Engl. J. Med. 385, 628â639 (2021).
Jostins, L. & Barrett, J. C. Genetic risk prediction in complex disease. Hum. Mol. Genet. 20, R182âR188 (2011).
Jostins, L. et al. Hostâmicrobe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119â124 (2012).
Liu, J. Z. et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47, 979â986 (2015).
Lee, J. C. et al. Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohnâs disease. Nat. Genet. 49, 262â268 (2017).
Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655â662 (2019).
Nishida, A. et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin. J. Gastroenterol. 11, 1â10 (2018).
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711â715 (2004).
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40â51 (2014).
Lu, R. M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020).
Scannell, J. W. et al. Predictive validity in drug discovery: what it is, why it matters and how to improve it. Nat. Rev. Drug Discov. 21, 915â931 (2022).
Ferreira, B. et al. Trends in 3D models of inflammatory bowel disease. Biochim. Biophys. Acta Mol. Basis Dis. 1870, 167042 (2024).
Lea T. in The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models (eds Verhoeckx, K. et al.) 103â124 (Springer, 2015).
Okayasu, I. et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98, 694â702 (1990).
Powrie, F., Leach, M. W., Mauze, S., Caddle, L. B. & Coffman, R. L. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 5, 1461â1471 (1993).
Kühn, R., Löhler, J., Rennick, D., Rajewsky, K. & Müller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263â274 (1993).
Neurath, M. F., Fuss, I., Kelsall, B. L., Stüber, E. & Strober, W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182, 1281â1290 (1995).
Boirivant, M., Fuss, I. J., Chu, A. & Strober, W. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188, 1929â1939 (1998).
Nenci, A. et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446, 557â561 (2007).
Mestas, J. & Hughes, C. C. W. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731â2738 (2004).
Parikh, K. et al. Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature 567, 49â55 (2019).
Almutary, A. G., Alnuqaydan, A. M., Almatroodi, S. A. & Tambuwala, M. M. Comparative analysis of the effect of different concentrations of dextran sodium sulfate on the severity and extent of inflammation in experimental ulcerative colitis. Appl. Sci. 13, 3233 (2023).
Yang, C. & Merlin, D. Unveiling colitis: a journey through the dextran sodium sulfate-induced model. Inflamm. Bowel Dis. https://doi.org/10.1093/ibd/izad312 (2024).
Baydi, Z. et al. An update of research animal models of inflammatory bowel disease. ScientificWorldJournal 2021, 7479540 (2021).
Chassaing, B., Aitken, J. D., Malleshappa, M. & Vijay-Kumar, M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 104, 15.25.1â15.25.14 (2014).
Strober, W., Nakamura, K. & Kitani, A. The SAMP1/Yit mouse: another step closer to modeling human inflammatory bowel disease. J. Clin. Invest. 107, 667â670 (2001).
Outtier, A. et al. Screening failure in a large clinical trial centre for inflammatory bowel diseases: rates, causes, and outcomes. Inflamm. Bowel Dis. 29, 1440â1445 (2023).
Vieujean, S. et al. Analysis of clinical trial screen failures in inflammatory bowel diseases (IBD): real world results from the international organization for the study of IBD. J. Crohnâs Colitis. https://doi.org/10.1093/ecco-jcc/jjad180 (2023).
Noor, N. M. & Raine, T. Innovations to improve the efficiency of phase II IBD clinical trials. Nat. Rev. Gastroenterol. Hepatol. 20, 555â556 (2023).
Bahnam, P. et al. Most placebo-controlled trials in inflammatory bowel disease were underpowered because of overestimated drug efficacy rates: results from a systematic review of induction studies. J. Crohns Colitis 17, 404â417 (2023).
Gordon, M., Lakunina, S., Sinopoulou, V. & Akobeng, A. Minimum sample size estimates for trials in inflammatory bowel disease: a systematic review of a support resource. World J. Gastroenterol. 27, 7572 (2021).
IheozorâEjiofor, Z. et al. Sampleâsize estimation is not reported in 24% of randomised controlled trials of inflammatory bowel disease: a systematic review. U. Eur. Gastroenterol. J. 9, 47â53 (2021).
De Cruz, P., Kamm, M. A., Prideaux, L., Allen, P. B. & Moore, G. Mucosal healing in Crohnâs disease: a systematic review. Inflamm. Bowel Dis. 19, 429â444 (2013).
Yoon, H. et al. Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis. Gastroenterology 159, 1262â1275 (2020).
Lahiff, C. et al. The Crohnâs Disease Activity Index (CDAI) is similarly elevated in patients with Crohnâs disease and in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 37, 786â794 (2013).
Dubinsky, M. C. et al. Challenges and opportunities in IBD clinical trial design. Gastroenterology 161, 400â404 (2021).
Wils, P. et al. Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. U. Eur. Gastroenterol. J. 11, 797â806 (2023).
Kerschbaumer, A. et al. Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. Nat. Med. 26, 974â980 (2020).
Sandborn, W. J. et al. Natalizumab induction and maintenance therapy for Crohnâs disease. N. Engl. J. Med. 353, 1912â1925 (2005).
Sandborn, W. J. et al. Vedolizumab as induction and maintenance therapy for Crohnâs disease. N. Engl. J. Med. 369, 711â721 (2013).
Motoya, S. et al. Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE 14, e0212989 (2019).
Monteleone, G. et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohnâs disease. N. Engl. J. Med. 372, 1104â1113 (2015).
Strand, V. Minimizing efficacy differences between phase II and III RCTs. Nat. Rev. Rheumatol. 16, 359â360 (2020).
Truelove, S. C. & Witts, L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. 2, 1041â1048 (1955).
Lightner, A. L. et al. Results at up to 30âyears after ileal pouch-anal anastomosis for chronic ulcerative colitis. Inflamm. Bowel Dis. 23, 781â790 (2017).
Khoudari, G. et al. Rates of intestinal resection and colectomy in inflammatory bowel disease patients after initiation of biologics: a cohort study. Clin. Gastroenterol. Hepatol. 20, e974âe983 (2022).
Bernstein, C. N. et al. Hospitalisations and surgery in Crohnâs disease. Gut 61, 622â629 (2012).
Atia, O. et al. Perianal Crohnâs disease is associated with poor disease outcome: a nationwide study from the epiIIRN cohort. Clin. Gastroenterol. Hepatol. 20, e484âe495 (2022).
Chin, Y. H. et al. Systematic review with meta-analysis: the prevalence, risk factors and outcomes of upper gastrointestinal tract Crohnâs disease. Dig. Liver Dis. 53, 1548â1558 (2021).
Vuyyuru, S. K. et al. Patients with Crohnâs disease and permanent ileostomy are universally excluded from clinical trials: a systematic review. Am. J. Gastroenterol. 118, 1285â1288 (2023).
Hanzel, J., Ma, C., Jairath, V. & IBD Trial Design Group Design of clinical trials for mild to moderate Crohnâs disease. Gastroenterology 162, 1800â1814 (2022).
Sedano, R. et al. Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trials. Inflamm. Bowel Dis. 28, 1293â1295 (2022).
Sedano, R. et al. Underrepresentation of minorities and underreporting of race and ethnicity in Crohnâs disease clinical trials. Gastroenterology 162, 338â340 (2022).
Cohen, N. A., Silfen, A. & Rubin, D. T. Inclusion of under-represented racial and ethnic minorities in randomized clinical trials for inflammatory bowel disease. Gastroenterology 162, 17 (2022).
Vieujean, S. et al. Is it time to include older adults in inflammatory bowel disease trials? A call for action. Lancet Healthy Longev. 3, e356âe366 (2022).
van Rheenen, P. F. et al. The medical management of paediatric Crohnâs disease: an ECCO-ESPGHAN guideline update. J. Crohns Colitis 15, 171â194 (2021).
Van Limbergen, J. et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 135, 1114â1122 (2008).
Croft, N. M. et al. Paediatric inflammatory bowel disease: a multi-stakeholder perspective to improve development of drugs for children and adolescents. J. Crohns Colitis 17, 249â258 (2022).
Crowley, E. et al. Impact of drug approval pathways for paediatric inflammatory bowel disease. J. Crohns Colitis 16, 331â335 (2022).
Thornton, H. Patient and public involvement in clinical trials. BMJ 336, 903â904 (2008).
Honap, S., Buisson, A., Danese, S., Beaugerie, L. & Peyrin-Biroulet, L. Patient and public involvement in research: lessons for inflammatory bowel disease. J. Crohns Colitis 17, 1882â1891 (2023).
Noor, N. M., Parkes, M. & Raine, T. Moving towards more patient-centred clinical trials in IBD. Nat. Rev. Gastroenterol. Hepatol. 18, 673â674 (2021).
US Food and Drug Administration. Considerations for the design and conduct of externally controlled trials for drug and biological products. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products (2023).
European Medicines Agency. ICH E10 choice of control group in clinical trialsâscientific guideline. EMA https://www.ema.europa.eu/en/ich-e10-choice-control-group-clinical-trials-scientific-guideline (2001).
Ravikoff, J. E., Cole, E. B. & Korzenik, J. R. Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives. Inflamm. Bowel Dis. 18, 2092â2098 (2012).
Rubin, D. T. et al. Inflammatory bowel disease patientsâ perspectives of clinical trials: a global quantitative and qualitative analysis. Crohns Colitis 360 3, otab079 (2021).
Inan, O. T. et al. Digitizing clinical trials. npj Digit. Med. 3, 1â7 (2020).
Rubin, D. T. et al. International perspectives on management of inflammatory bowel disease: opinion differences and similarities between patients and physicians from the IBD GAPPS survey. Inflamm. Bowel Dis. 27, 1942â1953 (2021).
Vamathevan, J. et al. Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov. 18, 463â477 (2019).
Jayatunga, M. K. P., Xie, W., Ruder, L., Schulze, U. & Meier, C. AI in small-molecule drug discovery: a coming wave? Nat. Rev. Drug Discov. 21, 175â176 (2022).
Bravo, Ã., Piñero, J., Queralt-Rosinach, N., Rautschka, M. & Furlong, L. I. Extraction of relations between genes and diseases from text and large-scale data analysis: implications for translational research. BMC Bioinforma. 16, 55 (2015).
Nayal, M. & Honig, B. On the nature of cavities on protein surfaces: application to the identification of drug-binding sites. Proteins 63, 892â906 (2006).
Costa, P. R., Acencio, M. L. & Lemke, N. A machine learning approach for genome-wide prediction of morbid and druggable human genes based on systems-level data. BMC Genomics 11, S9 (2010).
Rouillard, A. D., Hurle, M. R. & Agarwal, P. Systematic interrogation of diverse omic data reveals interpretable, robust, and generalizable transcriptomic features of clinically successful therapeutic targets. PLoS Comput. Biol. 14, e1006142 (2018).
Tropsha, A., Isayev, O., Varnek, A., Schneider, G. & Cherkasov, A. Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR. Nat. Rev. Drug Discov. 23, 141â155 (2023).
Li, X. et al. Development and validation of a novel computed-tomography enterography radiomic approach for characterization of intestinal fibrosis in Crohnâs disease. Gastroenterology 160, 2303â2316 (2021).
Stidham, R. W. et al. Assessing small bowel stricturing and morphology in Crohnâs disease using semi-automated image analysis. Inflamm. Bowel Dis. 26, 734â742 (2020).
Stidham, R. W. et al. Performance of a deep learning model vs human reviewers in grading endoscopic disease severity of patients with ulcerative colitis. JAMA Netw. Open. 2, e193963 (2019).
Bossuyt, P. et al. Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. Gut 69, 1778â1786 (2020).
Gottlieb, K. et al. Central reading of ulcerative colitis clinical trial videos using neural networks. Gastroenterology 160, 710â719 (2021).
Yao, H. et al. Fully automated endoscopic disease activity assessment in ulcerative colitis. Gastrointest. Endosc. 93, 728â736 (2021).
Gui, X. et al. PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system. Gut 71, 889â898 (2022).
Peyrin-Biroulet, L., Adsul, S., Dehmeshki, J. & Kubassova, O. DOP58 An artificial intelligence-driven scoring system to measure histological disease activity in ulcerative colitis. J. Crohns Colitis 16, i105 (2022).
Iacucci, M. et al. Artificial intelligence enabled histological prediction of remission or activity and clinical outcomes in ulcerative colitis. Gastroenterology 164, 1180â1188 (2023).
Arnold, C. Inside the nascent industry of AI-designed drugs. Nat. Med. 29, 1292â1295 (2023).
Exscientia. DSP-1181 https://www.exscientia.ai/dsp-1181 (2020).
Burki, T. A new paradigm for drug development. Lancet Digital Health 2, e226âe227 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05130866 (2024).
Businesswire. BenevolentAI announces positive topline safety and pharmacokinetic data from the phase Ia clinical study of BEN-8744 in healthy volunteers. businesswire.com https://www.businesswire.com/news/home/20240324322513/en/BenevolentAI-Announces-Positive-Topline-Safety-and-Pharmacokinetic-Data-from-the-Phase-Ia-Clinical-Study-of-BEN-8744-in-Healthy-Volunteers (2024).
Zilbauer, M. et al. A roadmap for the human gut cell atlas. Nat. Rev. Gastroenterol. Hepatol. 20, 597â614 (2023).
Ideker, T., Galitski, T. & Hood, L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. 2, 343â372 (2001).
Fiocchi, C. Inflammatory bowel disease: complexity and variability need integration. Front. Med. 5, 75 (2018).
Fiocchi, C. & Iliopoulos, D. IBD systems biology is here to stay. Inflamm. Bowel Dis. 27, 760â770 (2021).
Cusick, M. E., Klitgord, N., Vidal, M. & Hill, D. E. Interactome: gateway into systems biology. Hum. Mol. Genet. 14, R171âR181 (2005).
de Souza, H. S. P., Fiocchi, C. & Iliopoulos, D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat. Rev. Gastroenterol. Hepatol. 14, 739â749 (2017).
Subramanian, I., Verma, S., Kumar, S., Jere, A. & Anamika, K. Multi-omics data integration, interpretation, and its application. Bioinform Biol. Insights 14, 1177932219899051 (2020).
Peyvandipour, A., Saberian, N., Shafi, A., Donato, M. & Draghici, S. A novel computational approach for drug repurposing using systems biology. Bioinformatics 34, 2817â2825 (2018).
Lamb, J. et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929â1935 (2006).
Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl Med. 3, 96ra77 (2011).
Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437â1452 (2017).
Clark, P. M. et al. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases. Inflamm. Bowel Dis. 18, 2315â2333 (2012).
Collij, V., Festen, E. A. M., Alberts, R. & Weersma, R. K. Drug repositioning in inflammatory bowel disease based on genetic information. Inflamm. Bowel Dis. 22, 2562â2570 (2016).
Cai, X., Chen, Y., Gao, Z. & Xu, R. Explore small molecule-induced genome-wide transcriptional profiles for novel inflammatory bowel disease drug. AMIA Jt. Summits Transl Sci. Proc. 2016, 22â31 (2016).
Grenier, L. & Hu, P. Computational drug repurposing for inflammatory bowel disease using genetic information. Comput. Struct. Biotechnol. J. 17, 127â135 (2019).
McShane, L. M. et al. Criteria for the use of omics-based predictors in clinical trials. Nature 502, 317â320 (2013).
Otte, M. L. et al. Mucosal healing and inflammatory bowel disease: therapeutic implications and new targets. World J. Gastroenterol. 29, 1157â1172 (2023).
Argmann, C. et al. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut 72, 1271â1287 (2023).
Gilroy, D. W. Resolving inflammation. Nat. Rev. Immunol. 21, 620â621 (2021).
Steere, B. et al. Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study. Clin. Transl Gastroenterol. 14, e00578 (2023).
Johnson, T. et al. Mirikizumab-induced transcriptome changes in ulcerative colitis patient biopsies at weekâ12 are maintained through weekâ52. Clin. Transl Gastroenterol. 14, e00630 (2023).
Bourgonje, A. R., van Goor, H., Faber, K. N. & Dijkstra, G. Clinical value of multiomics-based biomarker signatures in inflammatory bowel diseases: challenges and opportunities. Clin. Transl Gastroenterol. 14, e00579 (2023).
Weersma, R. K., Xavier, R. J., IBD Multi Omics Consortium, Vermeire, S. & Barrett, J. C. Multiomics analyses to deliver the most effective treatment to every patient with inflammatory bowel disease. Gastroenterology 155, e1âe4 (2018).
Seyed Tabib, N. S. et al. Big data in IBD: big progress for clinical practice. Gut 69, 1520â1532 (2020).
Han, J. J. FDA Modernization Act 2.0 allows for alternatives to animal testing. Artif. Organs 47, 449â450 (2023).
Sato, T. et al. Single Lgr5 stem cells build cryptâvillus structures in vitro without a mesenchymal niche. Nature 459, 262â265 (2009).
Clevers, H. Modeling development and disease with organoids. Cell 165, 1586â1597 (2016).
Driehuis, E., Kretzschmar, K. & Clevers, H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 15, 3380â3409 (2020).
Han, Y. et al. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature 589, 270â275 (2021).
Perrone, F. & Zilbauer, M. Biobanking of human gut organoids for translational research. Exp. Mol. Med. 53, 1451â1458 (2021).
Cong, Y. et al. Drug toxicity evaluation based on organ-on-a-chip technology: a review. Micromachines 11, 381 (2020).
Matsui, T. & Shinozawa, T. Human organoids for predictive toxicology research and drug development. Front. Genet. 12, 767621 (2021).
Michiba, K. et al. Usefulness of human jejunal spheroid-derived differentiated intestinal epithelial cells for the prediction of intestinal drug absorption in humans. Drug. Metab. Dispos. 50, 204â213 (2022).
Jelinsky, S. A. et al. Molecular and functional characterization of human intestinal organoids and monolayers for modeling epithelial barrier. Inflamm. Bowel Dis. 29, 195â206 (2023).
Xu, P., Elizalde, M., Masclee, A., Pierik, M. & Jonkers, D. Corticosteroid enhances epithelial barrier function in intestinal organoids derived from patients with Crohnâs disease. J. Mol. Med. 99, 805â815 (2021).
Tindle, C. et al. A living organoid biobank of Crohnâs disease patients reveals molecular subtypes for personalized therapeutics. Preprint at bioRxiv https://doi.org/10.1101/2023.03.11.532245 (2023).
Bar-Ephraim, Y. E., Kretzschmar, K. & Clevers, H. Organoids in immunological research. Nat. Rev. Immunol. 20, 279â293 (2020).
Günther, C., Winner, B., Neurath, M. F. & Stappenbeck, T. S. Organoids in gastrointestinal diseases: from experimental models to clinical translation. Gut 71, 1892â1908 (2022).
Tian, C. M. et al. Stem cell-derived intestinal organoids: a novel modality for IBD. Cell Death Discov. 9, 1â16 (2023).
Leung, C. M. et al. A guide to the organ-on-a-chip. Nat. Rev. Methods Prim. 2, 1â29 (2022).
Xiang, Y. et al. Gut-on-chip: recreating human intestine in vitro. J. Tissue Eng. 11, 2041731420965318 (2020).
Loewa, A., Feng, J. J. & Hedtrich, S. Human disease models in drug development. Nat. Rev. Bioeng. 1, 545â559 (2023).
Rutherford, D. & Ho, G. T. Therapeutic potential of human intestinal organoids in tissue repair approaches in inflammatory bowel diseases. Inflamm. Bowel Dis. 29, 1488â1498 (2023).
Subbiah, V. The next generation of evidence-based medicine. Nat. Med. 29, 49â58 (2023).
DâAmico, F., Baumann, C., Rousseau, H., Danese, S. & Peyrin-Biroulet, L. Phase I, II and III trials in inflammatory bowel diseases: a practical guide for the non-specialist. J. Crohns Colitis 14, 710â718 (2020).
Allegretti, J. R. et al. Low-dose interleukin 2 for the treatment of moderate to severe ulcerative colitis. Gastroenterology 165, 492â495 (2023).
Harris, M. S. & Howden, C. W. Innovative trial designs in GI drug development: why trials succeed and fail. Gastroenterology 156, 1239â1242 (2019).
Wong, K. M., Capasso, A. & Eckhardt, S. G. The changing landscape of phase I trials in oncology. Nat. Rev. Clin. Oncol. 13, 106â117 (2016).
Davies, A. et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 15, 343â352 (2014).
Parikh, A. et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm. Bowel Dis. 18, 1470â1479 (2012).
Dumville, J. C., Hahn, S., Miles, J. N. V. & Torgerson, D. J. The use of unequal randomisation ratios in clinical trials: a review. Contemp. Clin. Trials 27, 1â12 (2006).
Sandborn, W. J. et al. Guselkumab for the treatment of Crohnâs disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology 162, 1650â1664.e8 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03926130 (2023).
Jahanshahi, M. et al. The use of external controls in FDA regulatory decision making. Ther. Innov. Regul. Sci. 55, 1019â1035 https://pubmed.ncbi.nlm.nih.gov/34014439/ (2021).
Honap, S. & Peyrin-Biroulet, L. Review article: externally derived control armsâan opportunity for clinical trials in inflammatory bowel disease? Aliment. Pharmacol. Ther. 58, 659â667 (2023).
Zayadi, A. et al. Use of external control arms in immune-mediated inflammatory diseases: a systematic review. BMJ Open 13, e076677 (2023).
Danese, S. et al. Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study. Clin. Gastroenterol. Hepatol. 19, 2324â2332.e6 (2021).
Croft, N. M. et al. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. Lancet Gastroenterol. Hepatol. 6, 616â627 (2021).
Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohnâs disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693â1700 (2012).
Pallmann, P. et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 16, 29 (2018).
Park, J. J. H., Mills & E. J., Wathen, J. K. Introduction to Adaptive Trial Designs and Master Protocols (Cambridge Univ. Press, 2023).
Woodcock, J. & LaVange, L. M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 377, 62â70 (2017).
Park, J. J. H. et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 20, 572 (2019).
DâAmico, F., Danese, S. & Peyrin-Biroulet, L. Adaptive designs: lessons for inflammatory bowel disease trials. J. Clin. Med. 9, 2350 (2020).
The I-SPY Trials (Quantum Leap Healthcare Collaborative, accessed 8 November 2023); https://www.ispytrials.org/.
Barker, A. et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97â100 (2009).
Rugo, H. S. et al. Adaptive randomization of veliparibâcarboplatin treatment in breast cancer. N. Engl. J. Med. 375, 23â34 (2016).
Sandborn, W. J. et al. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study. Clin. Gastroenterol. Hepatol. S1542-3565, 00007-1 (2023).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05499130 (2024).
ISRCTN. A clinical trial to see if a mesenchymal stem cells treatment called ORBCEL-CTM can help to treat primary sclerosing cholangitis, rheumatoid arthritis, lupus nephritis and Crohnâs disease. ISRCTN registry https://www.isrctn.com/ISRCTN80103507 (2023).
Pathiyil, M. M. et al. Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review. Lancet Gastroenterol. Hepatol. 8, 1143â1151 (2023).
DâHaens, G. et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 388, 2444â2455 (2023).
Sedano, R. et al. Design of clinical trials for mild to moderate ulcerative colitis. Gastroenterology 162, 1005â1018 (2022).
Vermeire, S. et al. Clinical remission in patients with moderate-to-severe Crohnâs disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389, 266â275 (2017).
Feagan, B. G. et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 397, 2372â2384 (2021).
Sandborn, W. J. et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 385, 1280â1291 (2021).
Sands, B. E. et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N. Engl. J. Med. 381, 1215â1226 (2019).
Sands, B. E. et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohnâs disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet 399, 2200â2211 (2022).
Gastroenterology Advances. Risankizumab meets all endpoints vs ustekinumab for Crohnâs disease. Gastroenterology Learning Network https://www.hmpgloballearningnetwork.com/site/gastro/advances/risankizumab-meets-all-endpoints-versus-ustekinumab-crohns-disease-0 (2023).
Ye, B. D. et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohnâs disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet 393, 1699â1707 (2019).
Grant, R. K. et al. The ACE (Albumin, CRP and Endoscopy) index in acute colitis: a simple clinical index on admission that predicts outcome in patients with acute ulcerative colitis. Inflamm. Bowel Dis. 27, 451â457 (2021).
Adams, A. et al. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut 72, 433â442 (2023).
Travis, S. et al. Vedolizumab for the treatment of chronic pouchitis. N. Engl. J. Med. 388, 1191â1200 (2023).
Panés, J. et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohnâs disease: a phase 3 randomised, double-blind controlled trial. Lancet 388, 1281â1290 (2016).
Panés, J. et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohnâs disease. Gastroenterology 154, 1334â1342 (2018).
Takeda. Takeda announces topline results of phase 3 ADMIRE-CD II trial of Alofisel (darvadstrocel) in complex Crohnâs perianal fistulas. Takeda https://www.takeda.com/newsroom/newsreleases/2023/Takeda-Announces-Topline-Results-of-Phase-3-ADMIRE-CD-II-Trial-of-Alofisel-darvadstrocel-in-Complex-Crohns-Perianal-Fistulas/ (2023).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05843578 (2024).
Leona M. and Harry B. Helmsley Charitable Trust. Endpoint development for ostomy clinical trials (EndO-Trial) consortium. Helmsley Charitable Trust https://helmsleytrust.org/grants/university-of-western-ontario-20196486/ (2024).
Lenze, E. J. et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 324, 2292â2300 (2020).
Simmons, L. A. et al. From hybrid to fully remote clinical trial amidst the COVID-19 pandemic: strategies to promote recruitment, retention, and engagement in a randomized mHealth trial. Digital Health 8, 20552076221129065 (2022).
Xue, J. Z. et al. Clinical trial recovery from COVID-19 disruption. Nat. Rev. Drug Discov. 19, 662â663 (2020).
Bouhnik Y, Hebuterne X, Raith M. P675 CT-Scout platform, the digital solution to boost patient recruitment in inflammatory bowel disease clinical trials: a multicentre prospective observational comparative study. ECCO https://www.ecco-ibd.eu/publications/congress-abstracts/item/p675-ct-scout-platform-the-digital-solution-to-boost-patient-recruitment-in-inflammatory-bowel-disease-clinical-trials-a-multicentre-prospective-observational-comparative-study.html (2023).
Bouhnik, Y., Louis, E. & Peyrin-Biroulet, L. Looking for innovative digital solutions to optimize patient recruitment in inflammatory bowel disease trials. Gastroenterology 158, 2306â2307 (2020).
CTMA. Clinical trials mobile application. CTMA https://www.ctma.fr/ (2023).
US Food and Drug Administration. Informed consent. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent (2023).
Mitchell, E. J. et al. e-Consent in UK academic-led clinical trials: current practice, challenges and the need for more evidence. Trials 24, 657 (2023).
Otobo, E. et al. P039 reinventing inflammatory bowel disease clinical trial recruitment using novel digital medicine tools. Inflamm. Bowel Dis. 25, S19âS20 (2019).
Howell, C. A. et al. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D). Gut 71, 2430â2438 (2022).
Do, N. T. T. et al. Implementation of point-of-care testing of C-reactive protein concentrations to improve antibiotic targeting in respiratory illness in Vietnamese primary care: a pragmatic cluster-randomised controlled trial. Lancet Infect. Dis. 23, 1085â1094 (2023).
Heida, A. et al. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin. Gastroenterol. Hepatol. 15, 1742â1749 (2017).
Ãstlund, I., Werner, M. & Karling, P. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease. Scand. J. Gastroenterol. 56, 38â45 (2021).
Berre, C. L. et al. Selecting end points for disease-modification trials in inflammatory bowel disease: the sPIRIT consensus from the IOIBD. Gastroenterology 160, 1452â1460.e21 (2021).
Jagannath, B. et al. A sweat-based wearable enabling technology for real-time monitoring of IL-1β and CRP as potential markers for inflammatory bowel disease. Inflamm. Bowel Dis. 26, 1533â1542 (2020).
Hirten, R. P. et al. Longitudinal monitoring of IL-6 and CRP in inflammatory bowel disease using IBD-AWARE. Biosens. Bioelectron. X 16, 100435 (2024).
Brosteanu, O. et al. Risk-adapted monitoring is not inferior to extensive on-site monitoring: results of the ADAMON cluster-randomised study. Clin. Trials 14, 584â596 (2017).
European Medicines Agency. Guideline on computerised systems and electronic data in clinical trials. EMA https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-computerised-systems-and-electronic-data-clinical-trials_en.pdf (2023).
Lensen, S. et al. Access to routinely collected health data for clinical trialsâreview of successful data requests to UK registries. Trials 21, 398 (2020).
Noor, N. & Siegel, C. A. Leveraging virtual technology to conduct clinical trials in inflammatory bowel disease. Gastroenterol. Hepatol. 19, 468â474 (2023).
Hanzel, J. et al. Approval timelines for advanced therapeutics in inflammatory bowel disease: a comparison between the European Medicines Agency and the Food and Drug Administration. Inflamm. Bowel Dis. https://doi.org/10.1093/ibd/izad168 (2023).
AbbVie. AbbVie receives orphan drug designation for investigational IL-23 inhibitor risankizumab from the U.S. Food and Drug Administration for the treatment of pediatric patients with Crohnâs disease. AbbVie News Center https://news.abbvie.com/2016-11-30-AbbVie-Receives-Orphan-Drug-Designation-for-Investigational-IL-23-Inhibitor-Risankizumab-from-the-U-S-Food-and-Drug-Administration-for-the-Treatment-of-Pediatric-Patients-with-Crohns-Disease (2023).
European Medicines Agency. EU/3/11/875 - orphan designation for treatment of pouchitis: Metronidazole. EMA https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-875 (2011).
BioSpace. Applied Molecular Transport announces FDA orphan drug designation granted to AMT-101 for treatment of pouchitis. BioSpace https://www.biospace.com/article/releases/applied-molecular-transport-announces-fda-orphan-drug-designation-granted-to-amt-101-for-treatment-of-pouchitis/ (2022).
Targan, S. R. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohnâs disease. N. Engl. J. Med. 337, 1029â1036 (1997).
Hanauer, S. B. et al. Maintenance infliximab for Crohnâs disease: the ACCENT I randomised trial. Lancet 359, 1541â1549 (2002).
Sands, B. E., Blank, M. A., Patel, K. & van Deventer, S. J. ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohnâs disease: response to infliximab in the ACCENT II Study. Clin. Gastroenterol. Hepatol. 2, 912â920 (2004).
Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462â2476 (2005).
Hanauer, S. B. et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohnâs disease: the CLASSIC-I trial. Gastroenterology 130, 323â333; quiz 591 (2006).
Sandborn, W. J. et al. Adalimumab for maintenance treatment of Crohnâs disease: results of the CLASSIC II trial. Gut 56, 1232â1239 (2007).
Sandborn, W. J. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142, 257â265 (2012).
Sandborn, W. J. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146, 85â95; quiz e14â15 (2014).
Sandborn, W. J. et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146, 96â109 (2014).
Sandborn, W. J. et al. Certolizumab pegol for the treatment of Crohnâs disease. N. Engl. J. Med. 357, 228â238 (2007).
Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699â710 (2013).
Feagan, B. G. et al. Ustekinumab as induction and maintenance therapy for Crohnâs disease. N. Engl. J. Med. 375, 1946â1960 (2016).
Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381, 1201â1214 (2019).
Sandborn, W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723â1736 (2017).
Loftus, E. V. et al. Upadacitinib induction and maintenance therapy for Crohnâs disease. N. Engl. J. Med. 388, 1966â1980 (2023).
Danese, S. et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 399, 2113â2128 (2022).
Sandborn, W. J. et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N. Engl. J. Med. 374, 1754â1762 (2016).
Sandborn, W. J. et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet 401, 1159â1171 (2023).
Ferrante, M. et al. Risankizumab as maintenance therapy for moderately to severely active Crohnâs disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 399, 2031â2046 (2022).
Peyrin-Biroulet, L. et al. The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study. U Eur. Gastroenterol. J. 11, 45 (2023).
Ferrante, M. et al. OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohnâs disease: results of the treat-through VIVID 1 study. J. Crohnâs Colitis 18, i7âi9 (2024).
AbbVie. Risankizumab (SKYRIZI®) met primary and key secondary endpoints in 52-week phase 3 maintenance study in ulcerative colitis patients. AbbVie News Center https://news.abbvie.com/2023-06-15-Risankizumab-SKYRIZI-R-Met-Primary-and-Key-Secondary-Endpoints-in-52-Week-Phase-3-Maintenance-Study-in-Ulcerative-Colitis-Patients (2023).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03341962 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05611671 (2024).
Vermeire, S. et al. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. Lancet Gastroenterol. Hepatol. 7, 1024â1035 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05507203 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05535946 (2023).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06052059 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05910528 (2024).
Allegretti, J. et al. Low dose IL-2 for the treatment of moderate to severe ulcerative colitis. Gastroenterology 160, S9âS10 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04987307 (2024).
Firoozbhakt, F., Sarkar, N., Gorski, K. & Tchao, N. Targeting improved T-reg selectivity with the IL-2 mutein efavaleukin alfa: rationale for IL-2 therapy in ulcerative colitis. U Eur. Gastroenterol. J. 11, 959 (2023).
Sands, B. E. et al. OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active ulcerative colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial. J. Crohns Colitis 18, i4âi5 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03599622 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05181137 (2023).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03677648 (2023).
Author information
Authors and Affiliations
Contributions
All authors contributed to the development of presented concepts and writing of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
S.H. served as a speaker, a consultant, an advisory board member and/or has received travel grants from Pfizer, Janssen, AbbVie, Takeda, Ferring and Pharmacosmos. V.J. has received consulting/advisory board fees from AbbVie, Alimentiv Inc., Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso Pharmaceuticals, Takeda, Teva, Topivert, Ventyx and Vividion; and speaker fees from AbbVie, Ferring, Bristol Myers Squibb, Galapagos, Janssen, Pfizer, Shire, Takeda and Fresenius Kabi. S.D. has served as a speaker, consultant and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor. L.P.-B. reports consulting fees from AbbVie, Abivax, Adacyte, Alimentiv, Amgen, Applied Molecular Transport, Arena, Banook, Biogen, Bristol Myers Squibb, Celltrion, Connect Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, IAC Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Nordic Pharma, Novartis, Oncodesign Precision Medicine, ONO Pharma, OSE Immunotherapeuthics, Pandion Therapeuthics, ParâImmune, Pfizer, Prometheus, Protagonist, Roche, Samsung, Sandoz, Sanofi, Satisfay, Takeda, Telavant, Theravance, Thermo Fischer, Tigenix, Tillots, Viatris, Vectivbio, Ventyx and Ysopia; grants from Celltrion, Fresenius Kabi, Medac, MSD and Takeda; lecture fees from AbbVie, Amgen, Arena, Biogen, Celltrion, Ferring, Galapagos, Genentech, Gilead, Janssen, Lilly, Medac, MSD, Nordic Pharma, Pfizer, Sandoz, Takeda, Tillots and Viatris; and travel support from AbbVie, Amgen, Celltrion, Connect Biopharm, Ferring, Galapagos, Genentech, Gilead, Gossamer Bio, Janssen, Lilly, Medac, Morphic, MSD, Pfizer, Sandoz, Takeda, Thermo Fischer and Tillots.
Peer review
Peer review information
Nature Reviews Drug Discovery thanks Kenneth Hung and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisherâs note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Honap, S., Jairath, V., Danese, S. et al. Navigating the complexities of drug development for inflammatory bowel disease. Nat Rev Drug Discov 23, 546â562 (2024). https://doi.org/10.1038/s41573-024-00953-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41573-024-00953-0